Interesting paper concerning valuation of antibody licensing deals.
Says the majority of pre-clinical deals attracted below $10M, depending on a whole range of factors such as the pharma involved, milestone payments, number of candidates, and royalty arrangement.
It would be good to see Perseis arrange a deal prior to NNZ outcome to provide some kind of safety net should NNZ flop.
While the money may not be uber great, a bluechip Big Pharma signing up for our antibodies would provide validation of a pipeline product and put us on the radar.
http://www.venturevaluation.com/vv_web/files/BIO_2011_deal_making_antibody.pdf
perseis - value of licensing
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |